Staurosporine (Synonyms: Antibiotic AM-2282; STS; AM-2282)

Name: Staurosporine
Brand: MedChemExpress
SKU: HY-15141
Rating: 5.0 (124 reviews)

Cat. No.: HY-15141 Purity: 99.81%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC₅₀s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC₅₀ of 3 μM. Staurosporine is an apoptosis inducer.

For research use only. We do not sell to patients.

Staurosporine Chemical Structure

CAS No. : 62996-74-1

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 135	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 135	In-stock	Estimated Time of Arrival: December 31
Solid
2 mg	USD 96	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 132	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 180	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 340	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 510	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 760	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 124 publication(s) in Google Scholar

Other Forms of Staurosporine:

Staurosporine (GMP) Get quote

120 Publications Citing Use of MCE Staurosporine

: Staurosporine purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta. 2018 Aug;1864(8):2600-2609. [Abstract]; Expression of Nogo-B and apoptosis-related proteins determined by Western blot analysis.

: Staurosporine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2017 Sep;50:30-37. [Abstract]; BV-2 cells are pretreated with or without Staurosporine (1 μM) for 30 min, and then incubated with 20 μM Aβ_1–42 for 24 h. The protein expression of TNF-α, IL-1β, and IL-6 are detected by western blot.

: Staurosporine purchased from MedChemExpress. Usage Cited in: Neuroscience. 2017 Dec 4;365:217-225. [Abstract]; PMA markedly reduces the protein level of GLT-1.

: Staurosporine purchased from MedChemExpress. Usage Cited in: Cancer Res. 2013 Apr 15;73(8):2574-86. [Abstract]; Cells are treated with the indicated concentrations of AZD8055, Torin2 or staurosporin overnight and analyzed by western blot using antibodies specific for the indicated proteins.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PKC Isoform Specific Products:

View All Isoforms

PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

View All PKA Isoform Specific Products:

View All Isoforms

PKA PKAR

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

PKC

6 nM (IC₅₀)

PKA

15 nM (IC₅₀)

c-Fgr

2 nM (IC₅₀)

Phosphorylase kinase

3 nM (IC₅₀)

S6 kinase (70 kDa)

5 nM (IC₅₀)

v-Src

6 nM (IC₅₀)

cdc2

9 nM (IC₅₀)

TPK-IIB/Syk

16 nM (IC₅₀)

Ca²⁺/CaM PK-I1

20 nM (IC₅₀)

MLCK

21 nM (IC₅₀)

61 nM (IC₅₀)

EGF-R

100 nM (IC₅₀)

ERK-1

1500 nM (IC₅₀)

CSK

2000 nM (IC₅₀)

IGF-IR

6150 nM (IC₅₀)

CK2

19500 nM (IC₅₀)

CK1

163500 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	EC₅₀	0.03 μM Compound: STS	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 29197730]
518A2	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24361521]
8505C	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
A2780	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
A2780	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
A2780	EC₅₀	0.12 μM Compound: STS	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 29197730]
A2780	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24361521]
A-375	IC₅₀	2.1 μM Compound: Staurosporine	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
A-431	IC₅₀	70 nM Compound: Staurosporine	Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay	[PMID: 22541051]
A549	IC₅₀	0.02 μM Compound: staurosporine	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25825934]
A549	IC₅₀	0.02 μM Compound: Staurosporine	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
A549	EC₅₀	0.04 μM Compound: STS	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 29197730]
A549	IC₅₀	0.6 μM Compound: STP	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24361521]
A549	IC₅₀	13.22 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
A549	IC₅₀	139.95 ng/mL Compound: Staurosporine	Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay	[PMID: 19138858]
A549	IC₅₀	139.95 ng/mL Compound: Staurosporine	Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay	[PMID: 19138858]
A549	GI₅₀	2.4 nM Compound: staurosporine	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
A549	IC₅₀	3.05 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay	[PMID: 24792811]
A549	IC₅₀	7.47 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
A549	IC₅₀	9.1 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
A549	IC₅₀	9.5 μM Compound: Staurosporine	Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay	[PMID: 34246754]
B16-F10	IC₅₀	2.82 μM Compound: Staurosporine	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 22503364]
BGC-823	IC₅₀	0.38 μM Compound: Staurosporine	Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
BGC-823	EC₅₀	26.83 μg/mL Compound: Staurosporine	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 21889345]
BGC-823	IC₅₀	6.83 μM Compound: Staurosporine	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method	[PMID: 23018096]
BJ	EC₅₀	> 40 μM Compound: STS	Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
BJ	IC₅₀	0.002 μM Compound: Staurosporine	Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
BT-549	IC₅₀	0.08 μM Compound: Staurosporine	Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
CAPAN-1	IC₅₀	0.0123 μM Compound: Staurosporine	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
CAPAN-1	IC₅₀	0.03 μM Compound: STS	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
CAPAN-1	IC₅₀	0.0546 μM Compound: Staurosporine	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
Ca-Ski	IC₅₀	0.01144 μM Compound: Staurosporine	Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
CCRF-CEM	IC₅₀	0.023 μM Compound: Staurosporine	Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
CHO-K1	GI₅₀	0.13 μM Compound: Staurosporine	Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay	[PMID: 21513294]
COLO 205	IC₅₀	< 0.1 μM Compound: Staurosporine	Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
DLD-1	IC₅₀	0.009 μM Compound: Staurosporine	Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
DLD-1	IC₅₀	0.009 μM Compound: Staurosporine	Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay	[PMID: 11591505]
DU-145	IC₅₀	0.5 μM Compound: Staurosporine	Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay	[PMID: 31120251]
FaDu	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
FaDu	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
FaDu	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
HaCaT	IC₅₀	1.6 μM Compound: Staurosporine	Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
HCT-116	IC₅₀	< 0.1 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
HCT-116	IC₅₀	0.0281 μM Compound: Staurosporine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
HCT-116	IC₅₀	0.03 μM Compound: Staurosporine	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
HCT-116	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
HCT-116	IC₅₀	0.0481 μM Compound: Staurosporine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
HCT-116	IC₅₀	0.055 μM Compound: Staurosporine	Cytotoxicity against human HCT116 cells by sulforhodamine B assay Cytotoxicity against human HCT116 cells by sulforhodamine B assay	[PMID: 29389122]
HCT-116	IC₅₀	13.2 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
HCT-116	IC₅₀	16.15 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
HCT-116	IC₅₀	39 nM Compound: Staurosporine	Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay	[PMID: 23232060]
HCT-116	IC₅₀	6.94 μM Compound: Staurosporine	Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35694689]
HCT-116	IC₅₀	8.86 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
HEK293	CC₅₀	0.00354 μM Compound: Staurosporine	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay	[PMID: 28624701]
HEK293	IC₅₀	0.0037 μM Compound: Staurosporine	Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM) Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM)	[PMID: 31252285]
HEK293	IC₅₀	0.056 μM Compound: Staurosporine	Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay	[PMID: 24763262]
HEK293	IC₅₀	0.077 μM Compound: staurosporine	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	[PMID: 12941331]
HEK293	IC₅₀	0.077 μM Compound: Staurosporine	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2 Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	[PMID: 15771419]
HEK293	IC₅₀	0.41 μM Compound: Staurosporine	Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
HEK293	IC₅₀	34.33 μM Compound: Staurosporine	Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay	[PMID: 35182815]
HeLa	IC₅₀	0.025 μM Compound: staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25825934]
HeLa	IC₅₀	0.025 μM Compound: Staurosporine	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
HeLa	IC₅₀	0.175 μM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
HeLa	IC₅₀	2.72 μM Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay	[PMID: 24792811]
HeLa	EC₅₀	29.12 μg/mL Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21889345]
HeLa	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21488655]
HeLa	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21388191]
HeLa	IC₅₀	9.12 μM Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 48 hrs by MTT method Antiproliferative activity against human HeLa cells after 48 hrs by MTT method	[PMID: 23018096]
HeLa S3	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa S3 cells measured after 72 hrs Cytotoxicity against human HeLa S3 cells measured after 72 hrs	[PMID: 32688198]
HepG2	IC₅₀	0.018 μM Compound: Staurosporine	Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay	[PMID: 28993106]
HepG2	EC₅₀	21.74 μg/mL Compound: Staurosporine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21889345]
HepG2	IC₅₀	4.14 μM Compound: Staurosporine	Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 23018096]
HepG2	IC₅₀	6.73 μM Compound: Staurosporine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method	[PMID: 23018096]
HepG2	IC₅₀	8.3 μM Compound: Staurosporine	Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA	[PMID: 23279864]
HepG2	IC₅₀	9.04 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
HL-60	IC₅₀	0.0076 μM Compound: Staurosporine	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
HL-60	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
HL-60	IC₅₀	0.041 μM Compound: Staurosporine	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
HMLE	IC₅₀	4.9 nM Compound: 1	Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay	[PMID: 33335665]
HT-29	ED₅₀	> 20 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 21973101]
HT-29	ED₅₀	0.0026 μM Compound: Staurosporine	Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay	[PMID: 21973101]
HT-29	EC₅₀	0.15 μM Compound: STS	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 29197730]
HT-29	EC₅₀	0.2 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
HT-29	IC₅₀	0.2 μM Compound: ST	Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
HT-29	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
HT-29	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24361521]
HT-29	GI₅₀	10.9 nM Compound: staurosporine	Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
HT-29	IC₅₀	2 nM Compound: Staurosporine	Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay	[PMID: 21428375]
HT-29	IC₅₀	2.5 nM Compound: Staurosporine	Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay	[PMID: 21513293]
HT-29	ED₅₀	2.6 nM Compound: staurosporine	Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay	[PMID: 19422206]
HT-29	IC₅₀	20 nM Compound: Staurosporine	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
HT-29	GI₅₀	3.6 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 21513294]
Huh-7	IC₅₀	0.23 μM Compound: Staurosporine	Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
HUVEC	IC₅₀	0.004 μM Compound: Staurosporine	Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay	[PMID: 22182929]
HUVEC	IC₅₀	0.004 μM Compound: Staurosporine	Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay	[PMID: 11591505]
HUVEC	IC₅₀	0.5 μM Compound: STS	Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 34671737]
Jurkat	IC₅₀	0.0393 μM Compound: Staurosporine	Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
Jurkat	IC₅₀	0.14 μM Compound: Staurosporine	Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
Jurkat	IC₅₀	3.2 μM Compound: Staurosporine	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
K562	IC₅₀	> 0.1 μM Compound: Staurosporine	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
K562	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
K562	IC₅₀	0.0768 μM Compound: Staurosporine	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
K562	IC₅₀	1.7 μM Compound: Staurosporine	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
K562	IC₅₀	153 μM Compound: STSP	Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26022079]
KB 3-1	IC₅₀	< 0.2 μM Compound: Staurosporine	Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay	[PMID: 28956915]
KOPN-8	EC₅₀	0.71 μM Compound: STS	Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
L02	IC₅₀	9.5 μM Compound: Staurosporine	Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
L929	IC₅₀	< 0.2 μM Compound: Staurosporine	Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay	[PMID: 28956915]
Leukemia cell	EC₅₀	0.35 μM Compound: STS	Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
LN-229	IC₅₀	0.003 μM Compound: STS	Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
LN-229	IC₅₀	0.0097 μM Compound: Staurosporine	Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
LoVo	IC₅₀	0.001 μM Compound: Staurosporine	Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
LoVo	IC₅₀	0.001 μM Compound: Staurosporine	Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay	[PMID: 11591505]
LOX IMVI	IC₅₀	7.15 μM Compound: Staurosporine	Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33601311]
MCF7	IC₅₀	0.013 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
MCF7	IC₅₀	0.064 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
MCF7	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
MCF7	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
MCF7	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
MCF7	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 29197730]
MCF7	IC₅₀	0.33 μM Compound: Staurosporine	Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA	[PMID: 31992477]
MCF7	IC₅₀	0.4 μM Compound: STP	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24361521]
MCF7	IC₅₀	0.52 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
MCF7	IC₅₀	1.8 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay	[PMID: 28956915]
MCF7	GI₅₀	11 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21513294]
MCF7	IC₅₀	16.06 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
MCF7	IC₅₀	180 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay	[PMID: 22541051]
MCF7	IC₅₀	2 μM Compound: Staurosporine	Inhibition of PKA in human MCF7 cells by array-based fluorescence assay Inhibition of PKA in human MCF7 cells by array-based fluorescence assay	[PMID: 18656369]
MCF7	IC₅₀	3.07 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22503364]
MCF7	IC₅₀	3.39 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay	[PMID: 31972394]
MCF7	IC₅₀	3.67 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay	[PMID: 33667848]
MCF7	IC₅₀	3.67 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay	[PMID: 32877804]
MCF7	IC₅₀	4.1 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34482273]
MCF7	IC₅₀	4.1 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34871842]
MCF7	IC₅₀	50 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21488655]
MCF7	IC₅₀	50 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21388191]
MCF7	IC₅₀	6.08 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 34743062]
MCF7	IC₅₀	6.3 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
MCF7	IC₅₀	7.25 μM Compound: Staurosporine	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35694689]
MCF7	IC₅₀	7.33 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay	[PMID: 32877804]
MCF7	IC₅₀	8.81 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay	[PMID: 31992477]
MCF7	IC₅₀	9.2 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31972394]
MDA-MB-231	IC₅₀	0.0008581 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
MDA-MB-231	IC₅₀	0.01 μM Compound: Staurosporin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.24 μM Compound: Staurosporine	Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
MDA-MB-231	IC₅₀	2.5 nM Compound: 1	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay	[PMID: 33335665]
MDA-MB-231	IC₅₀	4.25 μM Compound: Staurosporine	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay	[PMID: 32044580]
MDA-MB-231	IC₅₀	4.31 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay	[PMID: 32877804]
MDA-MB-231	IC₅₀	6.75 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay	[PMID: 33667848]
MDA-MB-231	IC₅₀	6.75 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay	[PMID: 32877804]
MDA-MB-231	GI₅₀	7.1 nM Compound: staurosporine	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
MDA-MB-453	IC₅₀	0.02351 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
MDA-MB-468	IC₅₀	0.15 μM Compound: Staurosporine	Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
MDA-MB-468	IC₅₀	4.37 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay	[PMID: 31972394]
MDA-MB-468	IC₅₀	6.46 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31972394]
MGC-803	IC₅₀	8.97 μM Compound: Staurosporine	Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 26900656]
MIA PaCa-2	IC₅₀	370 nM Compound: Staurosporine	Antiproliferative activity against MiaPaCa-2 cells by MTT assay Antiproliferative activity against MiaPaCa-2 cells by MTT assay	[PMID: 16403626]
MM1.S	IC₅₀	0.0442 μM Compound: Staurosporine	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
MV4-11	IC₅₀	0.05 μM Compound: Staurosporine	Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
N2a	IC₅₀	0.0113 μM Compound: Staurosporine	Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 28152427]
NALM-6	EC₅₀	1.4 μM Compound: STS	Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
NCI-H460	IC₅₀	> 0.1 μM Compound: Staurosporine	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
NCI-H460	IC₅₀	0.0597 μM Compound: Staurosporine	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
NCI-H460	IC₅₀	0.06 μM Compound: STS	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
NCI-H460	GI₅₀	3.6 μM Compound: Staurosporine	Cytotoxicity against human H460 cells after 48 hrs by SRB assay Cytotoxicity against human H460 cells after 48 hrs by SRB assay	[PMID: 21513294]
NIH3T3	EC₅₀	0.008 μM Compound: Staurosporine	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
NIH3T3	IC₅₀	0.008 μM Compound: ST	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
NIH3T3	EC₅₀	0.008 μM Compound: STS	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
NIH3T3	EC₅₀	0.008 μM Compound: STS	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 29197730]
NIH3T3	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24361521]
NIH3T3	IC₅₀	140.12 μM Compound: Staurosporine	Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay	[PMID: 24286761]
PBMC	IC₅₀	0.0002 μM Compound: Staurosporine	Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay	[PMID: 33248847]
PBMC	IC₅₀	0.016 μM Compound: staurosporine	Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA	[PMID: 18823784]
PBMC	IC₅₀	0.016 μM Compound: 1	Suppression of IL2 production in human PBMC after 24 hrs by ELISA Suppression of IL2 production in human PBMC after 24 hrs by ELISA	[PMID: 18585046]
PC-3	IC₅₀	0.017 μM Compound: Staurosporine	Cytotoxicity against human PC3 cells by sulforhodamine B assay Cytotoxicity against human PC3 cells by sulforhodamine B assay	[PMID: 29389122]
PC-3	IC₅₀	0.031 μM Compound: staurosporine	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25825934]
PC-3	IC₅₀	0.039 μM Compound: STU	Cytotoxicity against human PC3 cells after 72 hrs by SRB assay Cytotoxicity against human PC3 cells after 72 hrs by SRB assay	[PMID: 29558119]
PC-3	IC₅₀	4.91 μM Compound: Staurosporine	Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
PC-3	IC₅₀	5.92 μM Compound: Staurosporine	Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
RBL-2H3	IC₅₀	0.2 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-bet Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-bet	[PMID: 31879206]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-be Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-be	[PMID: 30711393]
RBL-2H3	IC₅₀	0.5 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA	[PMID: 31879206]
RBL-2H3	IC₅₀	0.7 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.8 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside	[PMID: 31879206]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA	[PMID: 31879206]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta	[PMID: 30711393]
Rec1	IC₅₀	0.0255 μM Compound: Staurosporine	Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
Sf21	IC₅₀	0.002 μM Compound: Staurosporine	Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	[PMID: 27137359]
Sf21	IC₅₀	0.027 μM Compound: staurosporine	Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	0.039 μM Compound: staurosporine	Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	0.49 μM Compound: staurosporine	Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	1325 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1533 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1646 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1701 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay	[PMID: 21441024]
SF-268	GI₅₀	0.044 μM Compound: Staurosporine	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 21513294]
Sf9	IC₅₀	> 18.5 μM Compound: Staurosporine	Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay	[PMID: 24786585]
Sf9	IC₅₀	0.0039 μM Compound: Staurosporine	Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay	[PMID: 30340900]
Sf9	IC₅₀	0.005 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.015 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.036 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.083 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.27 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.51 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	1.2 nM Compound: Staurosporine	Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay	[PMID: 27089211]
Sf9	IC₅₀	2.3 μM Compound: staurosporine	Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay	[PMID: 20580552]
ST486	IC₅₀	0.007 μM Compound: Staurosporine	Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
SUP-B15	EC₅₀	0.55 μM Compound: STS	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
SW 1116	EC₅₀	24.92 μg/mL Compound: Staurosporine	Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay	[PMID: 21889345]
SW 1116	IC₅₀	4.18 μM Compound: Staurosporine	Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 24286761]
SW 1116	IC₅₀	4.95 μM Compound: Staurosporine	Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method	[PMID: 23018096]
SW 1116	IC₅₀	8.32 μM Compound: Staurosporine	Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 21962523]
SW-1736	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
SW480	IC₅₀	< 0.1 μM Compound: Staurosporine	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
T47D	IC₅₀	11.7 μM Compound: Staurosporine	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay	[PMID: 33962153]
T47D	IC₅₀	4.52 μM Compound: Staurosporine	Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay	[PMID: 32044580]
TERT-RPE1	IC₅₀	0.0055 μM Compound: Staurosporine	Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis	[PMID: 33248847]
UoC-B1	EC₅₀	2 μM Compound: STS	Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
Vero	IC₅₀	0.0024 μM Compound: Staurosporine	Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay	[PMID: 28993106]
Vero	IC₅₀	0.028 μM Compound: Staurosporine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30743094]
WI-38	IC₅₀	24.41 μM Compound: Staurosporine	Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay	[PMID: 34246754]
Z-138	IC₅₀	0.0067 μM Compound: Staurosporine	Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
Z-138	IC₅₀	0.02 μM Compound: STS	Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
Z-138	IC₅₀	0.0418 μM Compound: Staurosporine	Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]

In Vitro

Staurosporine, widely used as a protein kinase C (PKC) inhibitor with a broad spectrum of activity, is an alkaloid which can be isolated from the culture broth of Streptomyces staurospores. MC3T3E-1 osteoblasts, expose to Staurosporine (100 nM) for 12 h, release an amount of LDH (12.4±3.1%) that is similar to that release by the control cells(10.0±2.4%), indicating the relative absence of lytic death, which occurs in necrosis. In addition, treatment with Staurosporine (100 nM) results in morphological changes, characteristic of apoptosis: a brightblue fluorescent condensed nuclei seen through a fluorescence microscope after Hoechst 33258-staining, and a reduction of cell volume^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The inhibitory effect of Staurosporine is statistically significant at around Wk 10 of tumor promotion. Although statistically significant inhibition is not obtained with 10 ng of Staurosporine in later weeks of the experiment, a decreasing tendency in the percentages of tumor bearing mice and in average numbers of tumors per mouse is apparent. Thus, Staurosporine slightly inhibits tumor promotion of Teleocidin, even at the dose at which Staurosporine itself induced tumors^[3]. Staurosponne (0.05 and 0.1 mg/kg intraperitoneal) attenuates the impaired perlormance of water maze and passive avoidance tasks, even though the drug administration began 2 weeks after the lesion. Moreover, Staurosporine (0.1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion. These results suggest that Staurosporine attenuates impairment of learning through reversal of damage to cholinergic neurons induced by basal forebrain-lesion^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

466.53

Formula

C₂₈H₂₆N₄O₃

CAS No.

62996-74-1

Appearance

Solid

Color

White to yellow

SMILES

O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83

Structure Classification

Initial Source

Microorganisms

Streptomyces staurosporeus

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL (133.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1435 mL	10.7174 mL	21.4348 mL
5 mM	0.4287 mL	2.1435 mL	4.2870 mL
10 mM	0.2143 mL	1.0717 mL	2.1435 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 3.33 mg/mL (7.14 mM); Suspension solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (290 KB) SDS (418 KB)

COA (262 KB) HNMR (185 KB) LCMS (603 KB) Elemental Analysis Report (119 KB)

Handling Instructions (2659 KB)

References

[1]. Meggio F, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234(1):317-22. [Content Brief]

[2]. Chae HJ, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000 Oct;42(4):373-81. [Content Brief]

[3]. Yoshizawa S, et al. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin.Cancer Res. 1990 Aug 15;50(16):4974-8. [Content Brief]

[4]. Nabeshima T, et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J Pharmacol Exp Ther. 1991 May;257(2):562-6. [Content Brief]

[5]. Yujie Ren, et al. The ORF3a Protein of SARS-CoV-2 Induces Apoptosis in Cells. Cell Mol Immunol. 2020 Jun 18;1-3. [Content Brief]

Animal Administration
^[3]^[4]

Mice^[3]
Female CD-I mice are used. Various amounts of Staurosporine in 10 μL of acetone are applied to the ears of 8-wk-old CD-I mice. The extent of irritation is expressed as the minimum dose of the compound causing irritation. Induction of HOC in Mouse Skin Staurosporine in 0.1 mL of acetone is applied to the skin of the backs of CD-I mice, and a crude enzyme extract is obtained from the skin 18 h later. HDC activity is expressed as pmol of CO₂ released per mg of protein per l h of incubation. Induction of ODC in Mouse Skin Staurosporine in 0.2 mL of acetone is applied to the skin of the backs of CD-I mice. After 4 h, a crude enzyme extract is prepared from the epidermis, and its ODC activity is measured. Enzyme activity is expressed as nmol of CO₂ per mg of protein per 30 min of incubation.
Rats^[4]
Male Kbl Wistar rats(weighing 270 to 310 g) are used. In the group which is given Staurosporine for 2 weeks, the water maze task and Staurosporine administration are started 2 weeks after the BF-lesion, and the passive avoidance task is carried out 4 weeks after the BFlesion. The rat received Staurosporine at doses of 0.01, 0.03, 0.1, and 0.3 mg/kg (i.p., N=10 in each group for 2 weeks) 30 mm prior to the water maze training sessions and the passive avoidance task acquisitiontrial. In the group which is given Staurosporine for 4 weeks, the drug is first given 2 weeks after the BF-lesion. The water maze task is carried out 4 weeks after the BF-lesion. The passive avoidance task is carried out 6 weeks after the BF-lesion. The rat received Staurosporine at 0.05, 0.1, and 0.2 mg/kg (i.p., N=10 in each group) once a day for 2 weeks before training, and for 2 weeks after the water maze training sessions and the passive avoidance task acquisition trial. Staurosporine is suspended in 0.3% of sodium carboxymethyl cellulose. The vehicle is administered to the non-lesioned controls and the lesioned controls on the same schedule as the Staurosporine-treated animals.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Meggio F, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234(1):317-22. [Content Brief]

[2]. Chae HJ, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000 Oct;42(4):373-81. [Content Brief]

[3]. Yoshizawa S, et al. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin.Cancer Res. 1990 Aug 15;50(16):4974-8. [Content Brief]

[4]. Nabeshima T, et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J Pharmacol Exp Ther. 1991 May;257(2):562-6. [Content Brief]

[5]. Yujie Ren, et al. The ORF3a Protein of SARS-CoV-2 Induces Apoptosis in Cells. Cell Mol Immunol. 2020 Jun 18;1-3. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1435 mL	10.7174 mL	21.4348 mL	53.5871 mL
	5 mM	0.4287 mL	2.1435 mL	4.2870 mL	10.7174 mL
	10 mM	0.2143 mL	1.0717 mL	2.1435 mL	5.3587 mL
	15 mM	0.1429 mL	0.7145 mL	1.4290 mL	3.5725 mL
	20 mM	0.1072 mL	0.5359 mL	1.0717 mL	2.6794 mL
	25 mM	0.0857 mL	0.4287 mL	0.8574 mL	2.1435 mL
	30 mM	0.0714 mL	0.3572 mL	0.7145 mL	1.7862 mL
	40 mM	0.0536 mL	0.2679 mL	0.5359 mL	1.3397 mL
	50 mM	0.0429 mL	0.2143 mL	0.4287 mL	1.0717 mL
	60 mM	0.0357 mL	0.1786 mL	0.3572 mL	0.8931 mL
	80 mM	0.0268 mL	0.1340 mL	0.2679 mL	0.6698 mL
	100 mM	0.0214 mL	0.1072 mL	0.2143 mL	0.5359 mL

Staurosporine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Staurosporine (Synonyms: Antibiotic AM-2282; STS; AM-2282)

Customer Review

Other Forms of Staurosporine:

120 Publications Citing Use of MCE Staurosporine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PKC Isoform Specific Products:

View All PKA Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Staurosporine Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Staurosporine (Synonyms: Antibiotic AM-2282; STS; AM-2282)

Customer Review

Other Forms of Staurosporine:

Staurosporine Related Antibodies

120 Publications Citing Use of MCE Staurosporine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PKC Isoform Specific Products:

View All PKA Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Staurosporine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Staurosporine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report